Q: On Aug 13, you answered questions regarding Well as " As WELL stock did well, the stock price set in the equity component of the deal was $11.80 (up from $9.80). Circle had very strong growth. " What did that mean? Can you provide some background about above statement? What is equity component in the sentence mean and where did the $11.8 price came from?
Q: The share price for Vitahub Corp has dropped about 30% from the peak since June 2021 and it seems to continue dropping. What are the reasons for the downtrend? Is this stock a buy, hold or sell considering the next 1 to 2 year performance?
Q: This company seems to have reasonable ROE (just under 20) and good growth but has sold off with several large blocks transacting recently despite positive analyst coverage. It reports this week so I don't plan to jump into a position but I wanted 5i's opinion on whether mid $30's represents an attractive entry point for a company that has exposure to a variety of Pharma companies? Would it be a buy, sell or hold for you and what would it take in terms of a news event or drop in price to make it a buy? What do you like and/or dislike about the company?
Thanks!
Q: Hi group I am light on Health care + Manufacturing stocks what are your top 3 recommendations in both stocks / ETFs and why Thanks for your guidance
Q: I am surprised at the beating they took for their adjusted guidance outlook only because earnings continue to beat. What is your opinion as to the future outlook and do you think things will get worse before they get better?
Your opinion is appreciated
Wondering if you could please give me your current take on Guardant Health considering their recent earnings and news about Covid testing. Are you still a strong advocate of holding this stock patiently, with the hope that a significant advancement will eventually propel the SP? Thank you.
Q: I bought GUD as a long term investment. It worries me when you say you are losing patience with it and I suspect you will take it out of the portfolio if you find a very compelling replacement for that sector. But has anything fundamentally changed from when you included it in the portfiloio besides the time it is taking to spend the horde of cash?
Q: I am having difficulty making sense of the recent loss for this company. The results appear to be penalized by losses applying to a change in the fair value of debentures as well as derivatives which together are greater than the EBITDA earnings. I was wondering how relevant these are to the company's prospects and whether the resulting valuation justified the fall in the share price. Thank you for your response.
Can you comment on the strong earnings reported by BCRX today. Should I sell and take profits or do you think the stock will continue to improve favorably?
Thank you.